Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects (Journal of Clinical Pharmacology (February 2007) 47:2 (218-226) DOI: 10.1177/0091270006296058);Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

Journal of Clinical Pharmacology

Volumn 47, Issue 2, 2007, Pages 218-226

  Kubitza, Dagmar ^a   Becka, Michael ^a   Zuehlsdorf, Michael ^a   Mueck, Wolfgang ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

BAY 59 7939; Body weight; Factor Xa inhibitors; Gender; Rivaroxaban

Indexed keywords

RIVAROXABAN;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PROTHROMBIN TIME; SEX DIFFERENCE;

EID: 33846448135     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008323722     Document Type: Erratum

References (22)

1. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 ; 140: 867-873.
2. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002 ; 36: 1512-1517.
3. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005 ; 127: 2049-2056.
4. Haslam DW, James WP. Obesity. Lancet. 2005 ; 366: 1197-1209.
5. National Institute of Diabetes & Digestive & Kidney Disease. Weight-control information network. Statistics related to over-weight and obesity. 2005. Available at: http://win.niddk.nih.gov/statistics/index.htm.
6. Powell A, Teichtahl AJ, Wluka AE, Cicuttini FM. Obesity: a preventable risk factor for large joint osteoarthritis which may act through biomechanical factors. Br J Sports Med. 2005 ; 39: 4-5.
7. Wendelboe AM, Hegmann KT, Biggs JJ, et al. Relationships between body mass indices and surgical replacements of knee and hip joints. Am J Prev Med. 2003 ; 25: 290-295.
8. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126: 429S - 456S.
9. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005 ; 78: 412-421.
10. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005 ; 61: 873-880.
11. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005 ; 3: 2479-2486.
12. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006 ; 4: 121-128.
13. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006 ; 114: 2374-2381.
14. Weinz C, Buetehorn U, Daehler HP, et al. Pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - in rats and dogs. Xenobiotica. 2005 ; 35: 891-910.
15. US Food and Drug Administration Center for Drug Evaluation and Research. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. 2002. Available at: http://www.fda.gov/cder/guidance/ 3615fnl.htm.
16. Turpie AGG, Eriksson BI, Mueck W, et al. Pharmacokinetic and pharmacodynamic analyses of rivaroxaban in patients undergoing orthopaedic surgery [abstract]. Pathophysiol Haemost Thromb. 2006 ; 35: A2 - A2. Abstract 1182.
17. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol. 2006 ; 46: 981-990.
18. Fragmin (dalteparin sodium injection) [prescribing information]. New York, NY: Pfizer; 2004. Available at: http://www.pfizer.com/pfizer/download/ uspi_fragmin.pdf.
19. Lovenox (enoxaparin sodium injection) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2005. Available at: http://products.sanofi- aventis.us/lovenox/lovenox.pdf.
20. Al Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost. 2005 ; 3: 100-102.
21. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 ; 141: 745-752.
22. Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004 ; 75: 204-212.